# EDGAR Filing Document

**Accession Number:** 0001623526
**File Stem:** 0001415889-25-017957
**Filing Date:** 2025-6
**Character Count:** 10030
**Document Hash:** fd9f567d021db7b92b99b8c6e39fdcce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-25-017957.hdr.sgml**: 20250623

**ACCESSION NUMBER**: 0001415889-25-017957

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250618

**FILED AS OF DATE**: 20250623

**DATE AS OF CHANGE**: 20250623

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Hoitt Jason
- **CENTRAL INDEX KEY:** 0001762572

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38938
- **FILM NUMBER:** 251065145

**MAIL ADDRESS:**
- **STREET 1:** STOKE THERAPEUTICS, INC.
- **STREET 2:** 45 WIGGINS AVENUE
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Stoke Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001623526
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 471144582
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 45 WIGGINS AVENUE
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730
- **BUSINESS PHONE:** 781-430-8200

**MAIL ADDRESS:**
- **STREET 1:** 45 WIGGINS AVENUE
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASOthera Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20141028

## Ex-24

**LIMITED POWER OF ATTORNEY**

The undersigned hereby constitutes and appoints Jonathan Allan and Thomas Leggett (each, an "***Attorney-in-Fact***"), as long as such individual is providing services to Stoke Therapeutics, Inc., a Delaware corporation (the "***Company***"), acting individually, as the undersigned's true and lawful attorney-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4, and 5, and any amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 (as amended, the "***Exchange Act***"), and the rules and regulations thereunder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Forms 3, 4, and 5, and any amendments thereto, and file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority, if required; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of the Attorney-in-Fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the Attorney-in-Fact may approve in the Attorney-in-Fact's discretion.

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and revocation, hereby ratifying and confirming all that the Attorney-in-Fact, or the Attorney-in-Fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing Attorney-in-Fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

The undersigned agrees that the Attorney-in-Fact may rely entirely on information furnished orally or in writing by the undersigned to the Attorney-in-Fact. The undersigned also agrees to indemnify and hold harmless the Company and the Attorney-in-Fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based on any untrue statement or omission of necessary facts in the information provided by the undersigned to the Attorney-in-Fact for purposes of executing, acknowledging, delivering and filing Forms 3, 4, or 5 (including amendments thereto) and agrees to reimburse the Company and the Attorney-in-Fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of, and transactions in securities issued by, the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact.

**IN WITNESS WHEREOF**, the undersigned has caused this Power of Attorney to be executed as of this 20<sup>th</sup> day of June, 2025.

By:

<u>/s/ Jason Hoitt</u>

Name:

Jason Hoitt

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Hoitt Jason<br><sub>(Last) (First) (Middle)</sub><br>C/O STOKE THERAPEUTICS, INC.<br>45 WIGGINS AVENUE<br><sub>(Street)</sub><br>BEDFORD, MA 01730<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Stoke Therapeutics, Inc. [ STOK ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-06-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Patient Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 1802 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (Right to Buy) | <sup>(1)</sup> | 2034-04-14 | Common Stock | 265000 | $12.21 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(2)</sup> | 2034-08-14 | Common Stock | 65000 | $14.25 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(3)</sup> | 2035-03-19 | Common Stock | 60000 | $8.33 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(4)</sup> | 2035-06-15 | Common Stock | 90000 | $11.70 | D |  |
| Restricted Stock Units | <sup>(5)</sup> | 2029-03-15 | Common Stock | 40000 | <sup>(6)</sup> | D |  |

---

### Footnotes:

(1) The option vested or vests as to 1/4 of the total award on April 8, 2025, with another 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

(2) The option shall  vest as to 1/4 of the total award on August 15, 2025, with another 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

(3) The option vested or vests as to 1/48 of the total award on April 15, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

(4) The option vested or vests as to 1/48 of the total award on July 16, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

(5) The award shall vest as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the issuer through each vesting date.

(6) Each restricted stock unit represents a contingent right to receive one share of the issuer's Common Stock upon settlement.

**Signature:** /s/ Jonathan Allan, Attorney-in-Fact  
**Date:** 2025-06-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**